Colorectal Cancer Screening Using Stool DNA Analysis in Clinical Practice: Early Clinical Experience with Respect to Patient Acceptance and Colonoscopic Follow-up of Abnormal Tests

Berger, Barry M.; Schroy, Paul C.; Rosenberg, Jennifer L.; Lai-Goldman, Myla; Eisenberg, Marcia; Brown, Trisha; Rochelle, Robert; Billings, Paul R.

doi:10.3816/ccc.2006.n.003

Cited by 23 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29, 71 Berger et al reported that most individuals undergoing sDNA who completed a mailed survey reported satisfaction with the sDNA testing process, and most reported that they would repeat testing if recommended by their physician. 72 A clear limitation of sDNA testing for the detection of CRC and large adenomas is that test sensitivity is based on a panel of markers that appears to identify the majority of but not all CRC. Further, it is not known what proportion of advanced adenomas is identified with the current commercial version (version 1.1) of the sDNA test.…”

Section: Fitmentioning

confidence: 99%

Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

Levin

Lieberman

McFarland

et al. 2008

CA: A Cancer Journal for Clinicians

1,557

916

View full text Add to dashboard Cite

In the United States, colorectal cancer (CRC) is the third most common cancer diagnosed among men and women and the second leading cause of death from cancer. CRC largely can be prevented by the detection and removal of adenomatous polyps, and survival is significantly better when CRC is diagnosed while still localized. In 2006 to 2007, the American Cancer Society, the US Multi Society Task Force on Colorectal Cancer, and the American College of Radiology came together to develop consensus guidelines for the detection of adenomatous polyps and CRC in asymptomatic average-risk adults. In this update of each organization's guidelines, screening tests are grouped into those that primarily detect cancer early and those that can detect cancer early and also can detect adenomatous polyps, thus providing a greater potential for prevention through polypectomy. When possible, clinicians should make patients aware of the full range of screening options, but at a minimum they should be prepared to offer patients a choice between a screening test that is effective at both early cancer detection and cancer prevention through the detection and removal of polyps and a screening test that primarily is effective at early cancer detection. It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening. (CA Cancer J Clin 2008;58:130-160.)

show abstract

Section: Fitmentioning

confidence: 99%

Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

Levin

Lieberman

McFarland

et al. 2008

CA: A Cancer Journal for Clinicians

1,557

916

View full text Add to dashboard Cite

show abstract

“…Stool DNA testing Stool DNA testing provides an acceptable noninvasive alternative for CRC screening that can identify earlystage CRC and adenomatous polyps in routine clinical practice [105] . Abbaszadegan [106] et al reported that this test could detect CRC related genetic alterations by analyzing stool DNA with a sensitivity of 64% and 20% and a specificity of 95% and 100% for long DNA and p16 respectively.…”

Section: Derivative Technique For Crc Screeningmentioning

confidence: 99%

Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging

Sun

Wu²,

Guan³

2008

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains a leading cancer killer worldwide. But the disease is both curable and preventable at an early stage. Regular CRC cancer screening has been shown to reduce the risk of dying from CRC. However, the importance of large-scale screening is only now starting to be appreciated. This article reviews a variety of imaging procedures available for detecting ulcerative colitis (UC) and Crohn's disease (CD), polyps and CRC in their early stage and also presents details on various screening options. Detecting, staging and re-staging of patients with CRC also require multimodality, multistep imaging approaches. Staging and re-staging with conventional colonoscopy (CC), computer tomography colonography (CTC), magnetic resonance colonography (MRC) and positron emission tomography/ c o m p u t e r t o m o g ra p hy c o l o n o g ra p hy ( P E T / C TC ) are of paramount importance in determining the most appropriate therapeutic method and in predicting the risk of tumor recurrence and overall prognosis. The advantages and limitations of these modalities are also discussed.

show abstract

“…With mail-in next-day delivery, geographic availability and access are no longer barriers. Patients surveyed about the commercially available versions of stool-based DNA screening tests have found them easy to use and acceptable [13]. Therefore the development of accurate fecal colonocyte DNA and mRNA markers has the potential to revolutionize screening for colorectal cancer.…”

Section: Rationale For Stool-based Biomarkers For Detection Of Colorementioning

confidence: 99%

Fecal DNA-based detection of colorectal neoplasia

Turgeon

Brenner²

2007

Curr colorectal cancer rep

View full text Add to dashboard Cite

Human DNA fragments, as well a as whole colonocytes, can be found in stool and interrogated for mutations associated with carcinogenesis. Multiplexed panels of point mutations in fecal DNA improved the sensitivity of cancer detection (51.6%; 95% CI, 34.8%-68%) compared with fecal occult blood testing (12.9%; 95% CI, 5.1-28.9). However, the multiplex panels are not more sensitive than fecal occult blood testing in detecting advanced adenomas. Markers of epigenetic events, such as DNA methylation of gene promoters in genes not previously known to be associated with carcinogenesis or colorectal cancer, have recently been shown to be potential markers for early detection. Future approaches to improve sensitivity of fecal DNA detection of colorectal adenocarcinoma may require the inclusion of epigenetic biomarkers, the use of colonocytes isolated from feces, or both.

show abstract

Colorectal Cancer Screening Using Stool DNA Analysis in Clinical Practice: Early Clinical Experience with Respect to Patient Acceptance and Colonoscopic Follow-up of Abnormal Tests

Cited by 23 publications

References 12 publications

Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging

Fecal DNA-based detection of colorectal neoplasia

Contact Info

Product

Resources

About